Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2

Journal of Korean Medical Science

Volumn 22, Issue 4, 2007, Pages 616-620

  Min, Sun Kim ^a   Kim, Sun Young ^a   Kim, Gu Hwan ^b   Han, Wook Yoo ^b   Dong, Whan Lee ^c   Lee, Dae Yeol ^a  

^a Chonbuk National University Medical School   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Soonchunhyang University   (South Korea)

Author keywords

Kir6.2 channel; Korean; Mutation; Neonatal diabetes; Permanent; Sulfonylurea

Indexed keywords

EID: 34548561525     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.4.616     Document Type: Article

References (18)

1. Shield JP. Neonatal diabetes: new insights into aetiology and implications. Horm Res 2000; 53 (Suppl 1): 7-11.
2. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP. Transient neonatal diabetes:widening the understanding of the etiopathogenesis of diabetes. Diabets 2000; 49: 1359-66.
3. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnki Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT. Activating mutations in the gene encoding the ATP-sensitive potassium channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350: 1838-49.
4. Inagaki N, Gonoi T, Clement JP, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995; 270: 1166-70.
5. Aschcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984; 312: 446-8.
6. Gribble FM, Reimann F. Sulfonylurea action revisited: the post-cloning era. Diabetelogia 2003; 46: 875-91.
7. Sagen JV, Raeder H, Eba H, Naim S, Kolbeinn G, Halvor B, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Sovik O, Njolstad PR. Permanent Neonatal Diabetes due to Mutations in KCNJ11 Encoding Kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53: 2713-8.
8. Hattersley AT, Ashcroft FM. Activating Mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights and new therapy. Diabetes 2005; 54: 2503-13.
9. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutation in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 2006; 49: 1190-7.
10. Suzuki S, Mukai T, Matsuo K, Ueda O, Ito Y, Makita Y, Fujieda K. KCNJ11 gene activating mutations in Japanese patients with neonatal diabetes mellitus. Horm Research 2005; 64 (Suppl 1): 136.
11. Gloyn AL, Reimann F, Girard C, Edghill EL, Proks P, Pearson ER, Temple IK, Mackay DJ, Shield JP, Freedenberg D, Noyes K, Ellard S, Ashcroft FM, Gribble FM, Hattersley AT. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 2005; 14: 925-34.
12. Yorifuji T, Nagashima K, Kurokawa K, Kawai M, Oishi M, Akazawa Y, Hosokawa M, Yamada Y, Inagaki N, Nakahata T. The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus. J Clin Endocrinol Metab 2005; 90: 3174-8.
13. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA 2004; 101: 17539-44.
14. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27: 18-20.
15. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004; 89: 5504-7.
16. Codner E, Flanagan S, Ellard S, Garcia H, Hattersley A. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 2005; 28: 758-9.
17. Klupa T, Edghill EL, Nazim J, Sieradzki J, Ellard S, Hattersley AT, Malecki MT. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia 2005; 48: 1029-31.
18. Trapp S, Proks P, Tucker SJ, Ashcroft FM. Molecular analysis of ATP-sensitive K channel gating and implications for channel inhibition by ATP. J Gen Physiol 1998; 112: 333-49.